£9,000 in excess savings? I’d buy 457 shares of this dividend stock to target a £1,100 extra income

Dividend stocks that consistently boost payouts can offer investors massive yields long term. Here’s a share that may be on track to do just that.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Dividend stocks are a terrific source of passive income. Even with higher interest rates making savings accounts more attractive, they still pale in comparison to some of the opportunities investors are able to capitalise on. Plus, despite popular belief, dividends don’t have to be reinvested to unlock chunky long-term earnings. In other words, investors can start reaping the rewards straight away. Here’s how.

Investing in a growing yield

Hunting for high-yielding enterprises is a common practice among income investors. After all, the larger the sustainable payout, the more money that will be earned. While that’s true in the short term, in the long run, the landscape changes drastically.

A merely modest yield today can potentially grow into a gargantuan one in the future. A perfect demonstration of this happened with Safestore over the last 13 years. Despite only offering a fairly average yield at the time, investors who bought and held its shares since then are reaping more than 50% returns from dividends alone today!

Therefore, investors should be focused on finding firms with the capacity to grow their payouts over time, regardless of the yield now. And that’s what’s brought Hikma Pharmaceuticals (LSE:HIK) back on my radar.

Dividend potential

It’s been a bit of a bumpy ride for Hikma shareholders these last few years as competition ramped up in its core US market. But since then, management’s focus on expanding its other divisions — like its Injectables segment — has steadily started steering operations back on track, and with it, the share price.

Despite these operational speedbumps, cash flows remained relatively robust, enabling the group to continue increasing dividend payments. As such, it now has an 11-year streak of hiking dividends, with payouts growing at an impressive average of 14.2% per year.

Why is that significant? At the current stock price, the dividend yield stands at a fairly lacklustre 2.9%. As such, investing £9,000 right now would translate into a passive income of just £261 per year. Obviously, that’s hardly anything to get excited about.

But what if the firm continues to increase its payouts over the next 11 years at the same pace? In this scenario, the passive income stream could increase to over £1,100 without having to put any additional capital in.

Risk and uncertainty

Like any investment, dividends come with risks, especially when making predictions about the future. Admittedly, the demand for generic pharmaceuticals isn’t likely to disappear any time soon. After all, critical drugs are coming off patent every year, and healthcare unaffordability in the US, among other places, provides powerful tailwinds for companies like Hikma.

However, the group isn’t operating in a monopoly and has a lot of competition to fend off, as previously mentioned. As such, even if management is able to continue raising payouts over the next decade, it could be at a slower pace than what’s historically been achieved.

Investors must consider the possibility of potentially earning less than expected. Nevertheless, the prospect of making hundreds of extra pounds each year without having to lift a finger or needing to reinvest makes it a risk worth taking, in my opinion. That’s why I’m thinking of adding this business to my portfolio once I have more capital to hand.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

Investing freedom — but inside a pension

Strapped consumers might be cutting back on investing, but they’re still keeping up their pension contributions. The only problem? A…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

Forget gold! I’d rather buy these 3 FTSE high-yielders in a Stocks and Shares ISA

Gold looks like a risky investment to me as the price hits an all-time high. I'm ignoring the fuss to…

Read more »

Young female business analyst looking at a graph chart while working from home
Growth Shares

This 55p UK stock could rise more than 300%, according to a City broker

This UK stock has fallen from above 800p to below 60p. But analysts at Citi believe it’s capable of a…

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

I think this FTSE 250 trust has all the right ingredients to lock in long-term profits

Today I'm examining the prospects of a private equity investment trust on the FTSE 250 that caught my attention recently…

Read more »

Young black man looking at phone while on the London Overground
Investing Articles

2 under-the-radar UK shares investors should consider snapping up

Two UK shares have caught the eye of our writer. She explains why investors should be taking a closer look…

Read more »

Investing Articles

Are these 2 ultra-high-yielding income stocks a good buy for me?

These two income stocks often split the debate amongst investors. So what does our writer think of them as potential…

Read more »

Senior woman potting plant in garden at home
Investing Articles

5% yield! This dividend stock could be great for my retirement

Our writer explains why this dividend stock appeals to her as she’s investing to build wealth to enjoy in the…

Read more »

A young Asian woman holding up her index finger
Investing Articles

I’d aim for a second income of £1,000 a month with this super-reliable dividend stock

I think a great way to build a second income stream is by investing in dividend stocks via a Stocks…

Read more »